VTX-2337 + pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in
women with recurrent or persistent, epithelial ovarian, fallopian tube or primary peritoneal
VTX-2337, a small molecule agonist of Toll-like Receptor 8 (TLR8), activates multiple
components of the innate immune system and is being developed as a novel therapeutic agent
for use in oncology. Experimental data obtained in an animal model of ovarian cancer
supports the combination of VTX-2337 with PLD. In this model, the combination of VTX-2337
and PLD resulted in a significant reduction in tumor growth compared to either agent alone
and an increase in the number of T lymphocytes infiltrating the tumor. The combination of
PLD and VTX-2337 has been tested in a small number of women with ovarian cancer in a Phase
1b study and appears to be generally well-tolerated.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: email@example.com
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.